Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › TG103 phase 3 vs dulaglutide (T2D)

TG103 phase 3 vs dulaglutide (T2D)

TG103 · t2d

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
TG103
Population
t2d
Phase
3
Duration
28 weeks

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
TG103 15 mg vs dulaglutide: HbA1c −1.38 %t2d china28———−1.4——————congress

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: TG103 phase 3 vs dulaglutide (T2D). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/tg103-phase-3-vs-dulaglutide/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.